Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22171710 | 0.96 | HTT (0.62) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL734427 | 0.92 | LMNA (0.61) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL735078 | 0.92 | LMNA (0.61) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL590358 | 0.92 | LMNA (0.61) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL17431706 | 0.88 | HTT (0.62) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6605706 | 0.87 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3694578 | 0.85 | TGM2 (0.60) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3697605 | 0.85 | TGM2 (0.60) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL24923326 | 0.85 | HTT (0.62) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6375258 | 0.85 | HTT (0.62) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893767-A1 | PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134482-A1 | PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |